OBI Pharma presents GlycOBI platform for next-gen antibody-drug conjugates at 2026 AACR meeting.

OBI Pharma announced ten poster presentations at the 2026 AACR Annual Meeting highlighting its GlycOBI platform for next-generation antibody-drug conjugates. The company showcased lead candidates targeting TROP2, Nectin-4, and dual targets, demonstrating improved pharmacokinetics and the ability to overcome drug resistance. Site-specific conjugation technology aims to enhance stability and reduce off-target toxicity for safer cancer treatments.